Command Palette

Search for a command to run...

Clinical Trials · NCT01408888

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

CompletedPhase 1Dulaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
29
Start date
Aug 2011
Locations
3 sites, United States
Primary endpoint
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin
View Dulaglutide compound reference